Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pia Moinzadeh

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Dermatologie (Heidelberg, Germany)|February 23, 2024
[Fibrosing diseases]Claudia Günther, Pia Moinzadeh
Dermatologie (Heidelberg, Germany)|November 13, 2025
[Capillaroscopy-a diagnostic window into the microcirculation]Suzan Al-Gburi, Pia Moinzadeh
Journal of the American Academy of Dermatology|October 19, 2010
Imatinib treatment of generalized localized scleroderma (morphea)Pia Moinzadeh, Thomas Krieg, Nicolas Hunzelmann
Journal of the American Academy of Dermatology|August 16, 2011
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosisPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Journal of Experimental Pharmacology|May 18, 2016
Pharmacology and rationale for imatinib in the treatment of sclerodermaPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Dermatologie (Heidelberg, Germany)|February 16, 2024
[Localized scleroderma]Suzan Al-Gburi, Alexander Kreuter, Pia Moinzadeh
Rheumatology (Oxford, England)|June 27, 2023
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis-caution is key in interpreting retrospective data: ReplyMichael Kreuter, Francesco Bonella, Pia Moinzadeh, et al.
Archives of Dermatological Research|April 25, 2007
Scleroderma -- news to tellBeate Eckes, Nicolas Hunzelmann, Pia Moinzadeh, et al.
Archives of Internal Medicine|June 20, 2012
Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover studyEvren Caglayan, Sarah Axmann, Martin Hellmich, et al.
Frontiers in Medicine|September 5, 2017
Pathophysiological Mechanisms in Sclerosing Skin DiseasesBeate Eckes, Fang Wang, Pia Moinzadeh, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Dermatologie (Heidelberg, Germany)|February 23, 2024
[Fibrosing diseases]Claudia Günther, Pia Moinzadeh
Dermatologie (Heidelberg, Germany)|November 13, 2025
[Capillaroscopy-a diagnostic window into the microcirculation]Suzan Al-Gburi, Pia Moinzadeh
Journal of the American Academy of Dermatology|October 19, 2010
Imatinib treatment of generalized localized scleroderma (morphea)Pia Moinzadeh, Thomas Krieg, Nicolas Hunzelmann
Journal of the American Academy of Dermatology|August 16, 2011
Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosisPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Journal of Experimental Pharmacology|May 18, 2016
Pharmacology and rationale for imatinib in the treatment of sclerodermaPia Moinzadeh, Nicolas Hunzelmann, Thomas Krieg
Dermatologie (Heidelberg, Germany)|February 16, 2024
[Localized scleroderma]Suzan Al-Gburi, Alexander Kreuter, Pia Moinzadeh
Rheumatology (Oxford, England)|June 27, 2023
Comment on: Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis-caution is key in interpreting retrospective data: ReplyMichael Kreuter, Francesco Bonella, Pia Moinzadeh, et al.
Archives of Dermatological Research|April 25, 2007
Scleroderma -- news to tellBeate Eckes, Nicolas Hunzelmann, Pia Moinzadeh, et al.
Archives of Internal Medicine|June 20, 2012
Vardenafil for the treatment of raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover studyEvren Caglayan, Sarah Axmann, Martin Hellmich, et al.
Frontiers in Medicine|September 5, 2017
Pathophysiological Mechanisms in Sclerosing Skin DiseasesBeate Eckes, Fang Wang, Pia Moinzadeh, et al.
Pageof 6